Podcast appearances and mentions of Jacob Thomas

community interview home angels comedians singer rainbow drag nonbinary chameleons reeve actor comedian kulin nation gasworks jacob thomas james mckenzie

Play Episode Listen Later Jul 14, 2023

Jacob Thomas & Stewart Reeve interviews with James McKenzie. Jacob Thomas designs and makes wings with the Rainbow Community Angels and joins us to celebrate Non-Binary People's Day and support our Drag Community. Home - rainbow community angels Singer, actor, comedian Stewart Reeve chats about his show Chameleon at Gasworks, July 27 to 29, and his amazing range of vocal interpretations. Interview starts 28:30. Chameleon | Gasworks Arts Park 3CR broadcasts from the stolen lands of the Kulin Nation.

Jacob Thomas - Web Development Cohort 59

Stories from the Hackery

Play Episode Listen Later Feb 15, 2023 8:44

Jacob Thomas graduated with full time Web Development Cohort 59. Before making the decision to pursue a career in software development, I spent my entire adult life just looking for a role that I could be passionate about. After a lot of experience in other fields, and after years of circling the idea of working as a software engineer, I finally found myself an opportune time to study and make the switch. I have never enjoyed learning so much in my life. When I'm coding, I feel like I am doing what I was meant to do: solving problems, thinking through logic and finding ways to make things more efficient. I finally found something I can be good at and enjoy. I am excited to see where this new career will take me.

cohorts web development jacob thomas

Northwest Montana History Museum Volunteer Jacob Thomas 10-24-22

volunteers history museum northwest montana jacob thomas john hendricks robin mitchell

Play Episode Listen Later Oct 24, 2022 8:43

Northwest Montana History Museum Volunteer Jacob Thomas joined the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Monday, October 24th, 2022 to talk about upcoming performance.

Hard & Difficult Conversations - Jacob Thomas, Communications Director at Common Defense

AllVoices, Reimagining Company Culture

Play Episode Listen Later Sep 20, 2022 29:48

Welcome to Reimagining Company Culture, a series discussing emerging trends and priorities shaping the future of workplace culture and employee wellbeing. We highlight thought leaders who are constantly evolving their strategy and can provide insight to folks about how to address new business challenges. AllVoices is on a mission to create safe, happy, and healthy workplaces for all, and we're excited to learn from experts who share our mission. In this episode of Reimagining Company Culture, we're chatting with Jacob Thomas, Communications Director at Common Defense. Jacob now consults and contracts with multiple community and national organizations advancing civil and human rights and is the Communications Director for Common Defense, the largest organization of grassroots progressive veterans in the nation.Tune in to learn Jacob's thoughts on advice for managers navigating difficult conversations, creating sustainable change, going above and beyond with DEi training, and more!About AllVoices In today's workforce, people often don't feel empowered to speak up and voice their opinions about workplace issues, including harassment, bias, and other culture issues. This prevents company leadership from making necessary changes, and prevents people from feeling fulfilled, recognized, and included at work. At AllVoices, we want to change that by providing a completely safe, anonymous way for people to report issues directly to company leaders. This allows company leadership real transparency into what's happening in their companies—and the motivation to address issues quickly. Our goal is to help create safer, more inclusive companies.

dei difficult conversations communications director future of workplace jacob thomas common defense

Masterclass // Part 13: The Coming of the Kingdom // Jacob Thomas

Rolling Hills Community Church - Nolensville Campus

Play Episode Listen Later Jul 17, 2022 34:19

Passages that address the end times are often hard to understand and difficult to apply to our daily lives. Jesus in Mark 13 tells His disciples these tough things not so they will start trying to predict when they would come, but so they would be ready when they did. Jesus is calling them to vigilant discipleship through the hard times and to be faithful ‘til the end. He encourages them to be faithful by being watchful. Watchfulness is the spiritual discipline of guarding our hearts and minds in the word, in prayer, and in community faithfully until He returns.

jesus christ kingdom religion christianity tennessee masterclass passages watchfulness jeff simmons jacob thomas

Ep 510 Mike Large, Jacob Thomas, Max Shippee

The Gym Lords Podcast

Play Episode Listen Later Jul 11, 2022 89:29

This Episode we interview Mike Large, Jacob Thomas, Max Shippee about their take on being a Gym Owner. Welcome to the Gym Lords Podcast, where we talk with successful gym owners to hear what they're doing that is working RIGHT NOW, and to hear lessons and failures they've learned along the way. We would love to share your story! If you'd like to be featured on the podcast, fill out the form on the link below. https://gymlaunchsecrets.com/podcast

large gym owners jacob thomas

NW MT History Museum Executive Director Jacob Thomas joined the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Thursday June 23, 2022 to talk about new Exhibition GRAND OPENING, Kalispell: Montana's Eden on Thursday, June 30th, 5-7pm at The Northwest Montana History Museum.

executive director executives history museum jacob thomas john hendricks robin mitchell kalispell montana

ASCO22: Key Posters on Advances in Immunotherapy

ASCO Daily News

Play Episode Listen Later May 27, 2022 21:37

Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh's Hillman Cancer Center, share the latest news on immunotherapy trials KEYNOTE-A10, LIBRETTO-001, and other key IO studies across tumor types featured at the 2022 ASCO Annual Meeting. Transcript Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Diwakar Davar, and I'm an assistant professor of Medical Oncology in phase 1 therapeutics, at the University of Pittsburgh's Hillman Cancer Center, and the guest host of today's podcast. I'm delighted to welcome Dr. Jason Luke to this podcast. He's the director of the Cancer Immunotherapeutic Center at the Hillman Cancer Center, University of Pittsburgh, and a great colleague and friend. Today we'll be discussing some key posters that highlight some advances in immunotherapy that will be featured and the 2022 ASCO Annual Meeting. You will find our collective disclosures in the show notes and the disclosures of all guests on the podcast are available on our transcripts at asco.org/podcasts. So, Jason, thank you for coming on the podcast today. Dr. Jason Luke: Well, thanks very much for the invitation. I always love doing these podcasts for ASCO, and never love anything more than hanging out with my friend Diwakar Davar. Dr. Diwakar Davar: Well, thank you! Below are the abstracts we've selected. We will start with Abstract 2504. This is a phase 1 trial of the TIM-3 inhibitor cobolimab monotherapy, singly and in combination with the PD-1 inhibitors nivolumab or dostarlimab. Phase 1 data from the AMBER trial with the presenting author being Dr. Gerald Falchook. And this is a trial that initially started several years ago. And I know Jason, that you were involved with the inception of this agent, that TIM-3 inhibitor. So, walk us through, TIM-3. It's a third-generation checkpoint, we now have TIGIT LAG coming into the landscape. Definitely a first indication for LAG-3 melanoma with a positive trial, RELATIVITY 047. So, where are we with TIM-3? Why should we be excited about TIM in general, and this data in particular? Dr. Jason Luke: It is quite exciting, especially building off the recent data that we saw for relatlimab or LAG-3 because it's becoming clearer that a number of these other immune checkpoints that we have been talking about for many years, actually really can be effective when used in the right setting. So, this drug, this anti-TIM-3 antibody cobolimab monotherapy, as you mentioned, started out in a phase 1 clinical trial dating all the way back to I think about 2015. And that was at the time in immuno-oncology when everybody was so excited, [and] they thought everything was going to work immediately. Subsequent to that, obviously, we've had some hurdles that we've had to come over. But we're coming back to some of these agents now, which are looking very exciting. So, just in the same way we think about blocking PD-1 or now blocking LAG-3 to reinvigorate T cells in the tumor microenvironment, there's a good chance and a high probability based on preclinical data that blocking TIM-3 could be just as effective as blocking LAG-3, so to say. Now, one thing that I note in this abstract is really the safety finding and early PK analysis. And so, this is the important work we do early on to understand the drug. It's important to be aware that in a study like this, it's very hard to seek efficacy signals. So, when you see this poster, really, you probably shouldn't be thinking, ‘Oh, this is a frontline phase 3 trial,' but rather that the efficacy is going to be a secondary consideration. Rather, what's quite important is looking at the properties of the drug and looking at the safety signals around that. And what we can see here is that TIM-3 appears to be quite safe when blocking it in conjunction with anti-PD-1 across several different tumor types. And that really sets the stage then to think about moving this into earlier lines of therapy across many different cancers. And so, here we see advanced solid tumors but focused on lung cancer and melanoma and kind of the usual tumors we think about, and people can keep their eyes open because there are other posters of this molecule with PD-1 in some of the other sections outside of developmental therapeutics. Now, one thing I would like to get your opinion on because your group has focused a lot on TIM-3, as I described it as this T cell centric mechanism to reinvigorate exhausted T cells. But it's possible that TIM-3 does other things as well. And I don't know if you want to comment on that or give any other feedback that you've had when thinking about this AMBER Trial. Dr. Diwakar Davar: That was an excellent summary, Jason, of really what is a truncated 8-year track record of developing this agent all the way from 2015. But you bring up a very interesting point, which is: exactly what does this drug does in the non-T-cell compartment? Some very interesting data from Brian Ruffell in a paper that was published about 3 years ago now suggested that TIM-3 was actually potentially a myeloid checkpoint, meaning that, in a tumor model in which Dr. Ruffell was studying this in the context of breast cancer, the drug primarily appeared to work on the effect of antigen-presenting cells and augment the presentation of antigen to T cells suggesting that it may be, in addition to being a chronicle T cell exhaustion marker, it may also be reinvigorating antigen-presenting cells. And the question of whether or not the role of TIM-3 on APCs as well as the role of TIM-3 on T cells, and which of these compartments are more important, and how these compartments segregate in any given cancer across many different lines of therapy will hopefully be something that we disengage, and understand a little bit better as we look at biomarkers of this drug across different settings. And especially to that point, Jason, the biomarker question, you'll notice that very interestingly, that was a signal in which that drug had a certain response rate. Again, as you correctly point out, we cannot read too much into response rates in very small patient numbers. But very interestingly, there was a slightly higher response rate at the 300 milligrams, which is not the top dose level of the drug, and a slightly lower response rate at the ceiling dose of the drug that was tested, 900 milligrams, leading the investigators to conclude that the RP2D, was actually 300 milligrams every 3 weeks and not 900 milligrams. What are your thoughts on dose in the context of immunotherapy (IO) drug development? And why might it be that 300 is the optimal dose as opposed to 900? Dr. Jason Luke: That's a complicated question. I mean, when we think about checkpoint blockade, we classically think about it as only blocking on T cells. But to your point, if there are multiple mechanisms in play, sort of modulating other cell compartments actually may start to do different things at different doses that maybe weren't our primary intent as we went into the trial. That's a little bit of hand waving, immunologic hand waving, but I think the data are the data and once we hit an effective dose level, there's really no need to really push the dose that much further. But that really emphasizes the importance of these kinds of early phase clinical trials. So, I'm really looking forward to seeing this data. For disclosure, obviously, we have both been investigators on this trial. But we're very excited about the idea that there may be hope for a fourth checkpoint to come forward in the field beyond just PD-1 CTLA-4, and LAG-3, maybe now here with TIM-3. Dr. Diwakar Davar: So, with that we'll go to the next abstract and that is Abstract 2516, “Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.” So, this is an mRNA vaccine from our good friend, BioNTech. And that's been essentially evaluated in the context of highly lethal cancer, pancreatic ductal cancer, and specifically in the context of adjuvant vaccines, specifically in the setting of patients who had followed definitive pancreatic cancer surgery. So, Jason, you know a lot of neoantigen vaccines, you've led some of these trials, really, the neoantigen vaccine is really the primary reason we are actually having an in-person meeting this year, because if not for this company and others like this, really this pandemic would not be behind us. What are your thoughts on the role of neoantigen vaccines in cancer therapeutics, and also, particularly this particular trial in the data, the immunological data, and the clinical data regarding the development of neoantigen-specific T cells in this setting, and what this means for you? Dr. Jason Luke: Right. So, the idea of targeting neoantigens as cancer immunotherapy was really all the rage a few years back, and it was thought based on preclinical animal models that this was just going to be the secret sauce, and this would be the new targeted therapy for immunotherapy. And it isn't to say that that's not true, but the first generation of neoantigen, peptide-based vaccines for the most part, unfortunately, just kind of didn't end up moving the needle the way we had hoped. The question then was raised: is that because targeting neoantigens isn't reasonable, or is that because the setting where we were trying to do it in the refractory disease area was not the optimal way to leverage this? And so, a couple of different companies and trials now are coming forward looking at targeting neoantigen in a minimal residual disease setting where the idea could be that immunologic responses that you could generate wouldn't be hampered by all the immunosuppression associated with the tumor microenvironment. And so, here we have this molecule, which you eloquently pronounced, ‘autogene cevumeran.' It's an RNA-lipoplex neoantigen vaccine. So, it's not a peptide. It's more like the COVID-19 vaccines actually. And it's being given after surgery, followed by anti-PD-L1 followed by chemotherapy. So, it's a complicated regimen, but it's very intriguing these early data, which do show that the patients who got the vaccine seemed to have better and longer-term outcomes. But then as you emphasize, really, I think probably what's at the heart of this that really makes it exciting is their ability to immune monitor the patients, meaning to look for antigen-specific immune cells from the peripheral blood in these patients to be able to identify those immune responses as being specific to cancer. Because this kind of a clinical trial, it's still signal seeking and proof of concept kind of trial. In order to actually establish that a vaccine approach in a post-surgical setting would have efficacy, we need to do a large randomized trial. And so, this is not that yet. But I think these data really point in the direction that that could be a reasonable thing to try. And when you think about pancreatic cancer, where we've made no success with immunotherapy, really in a meaningful way in terms of checkpoint blockade, at least, that's pretty exciting actually to think about. I would actually marry this dataset with another that we actually saw at the American Association for Cancer Research (AACR) meeting that also looked at neoantigen targeting and antigen-specific responses in colorectal cancer, again, and in a similar setting with the minimal residual disease setting. And so, I think this highlights that we may need to start thinking about using immunotherapy in different ways than we had before. Obviously, everybody knows about using PD-1 blockade in lots of different cancer types that are really for metastatic disease, or maybe even for adjuvant now in melanoma a little bit. But maybe there's this space, which is the minimal residual disease setting where you might be able to detect by ctDNA after surgery, the patients are still positive. And maybe you could treat that before there's visible cancer, and maybe certain immunotherapies could be more valuable in that setting than others. And that's where I think maybe some of these mRNA technologies really might find their sweet spot. So, coming back to this abstract, I think really, the emphasis point here is the novelty of generating patient-specific neoantigen vaccines, and then being able to track linearly over time the immune response against those vaccines. I think with that kind of technology and being able to leverage that, I think we're really headed towards a real shift in the way we think about managing cancer in a post-surgical setting, again, thinking about MRD, or minimal residual disease, maybe in a way that our leukemia colleagues have been thinking it about for a long time. Dr. Diwakar Davar: That's an excellent summary of a very, very complicated, both setting, and in this case, a therapeutic landscape. So, well said, well summarized, and we'll now pivot to Abstract 2514. So, this is ‘Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study' [and] the presenting author is Dr. Aung Naing from [The University of Texas] MD Anderson [Cancer Center]. So, Jason, you know, with checkpoints, we've got so many thoughts about checkpoints, particularly given the rather unfortunate failure of BEMPEG in the context of melanoma. So, we've got lots of interesting cytokines that we think of as important in the context of immuno-oncology 2, certainly 12, 15. You've been very involved with IO-15. We've got a lot of clinical trials studying IL-12. And now we've got one studying IL-7. So, tell us what do you think of this IL-7 targeting approach in the context of cytokine-based therapeutics? Dr. Jason Luke: I think it's really important to emphasize on first principles, for those that are listening, who don't think about immunology all the time that not all cytokines are the same thing. So, interleukin 2 that many people have heard of is very different actually than interferon. And that's very different from many of the other cytokines, the ILs, and everything, right? So, IL-7 is a very potent cytokine that's associated with the expansion of immune responses, and that can drive interferon gamma-dependent effects. And you should hear whenever I say interferon-gamma is sort of a link through to PD-1 responsiveness. Because we think the mechanism that underpins anti-PD-1 effectiveness in patients really is interferon gamma biology. So, IL-7 has been a molecule, it's been of a lot of interest but really was too toxic to try to deliver. But now we have novel drug delivery sorts of approaches that are being developed to try to bring the drug in, in a way that doesn't cause such systemic toxicity. So, in this clinical trial, this NT-I7 molecule is given intramuscularly, every 6 weeks in conjunction with pembrolizumab, and very interestingly, in a small number of patients, but there were resist responses observed across a series of tumors that you really wouldn't expect should be responsive in any way to pembrolizumab alone. And so, we're talking about microsatellite stable colorectal cancer, pancreatic cancer, and some others as well. And in conjunction with that, they were able to identify some of the biomarker effects we would think we would see with IL-7, such as expansion of peripheral immune compartments. And the toxicity profile was really consistent with what we've seen with fevers and chills, but manageable in a way that previous approaches really weren't. So, I think this is really exciting because I think the idea here then is with this IL-7 approach, we might expand the kinds of cancers that we could go after, in conjunction with anti-PD-1 again, pancreas, colorectal cancer. I think that's really where the unmet need lies in oncology. So, I really applaud these kinds of approaches and several of these cytokine approaches, and what we're going to talk about them, I think, have the potential to do that over the next couple of years. Dr. Diwakar Davar: Excellent! Pivoting now to a different cytokine, but one that was alluded to before IL-12. So, Abstract 2518 is ‘Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies,' and the presenting author here is Dr. Julius Strauss of the NCI Cancer Center and the Clinical Center of the National Cancer Institute at the National Institutes of Health. So, what do you think, Jason, about the role of the HPV targeting vaccine, in this case, that was added to IL-12 immune-cytokine and bintrafusp alpha contextualizing the recent data that we have of bintra along with what is a very interesting result here? Dr. Jason Luke: Yes, I think building on the last abstract where we talked about IL-7 as some novel biology now we move to IL-12, which again introduces other biology. So, interleukin-12 is a complicated cytokine, but one that's strongly associated with initial immune responses or immune priming, as well as enhancement of anti-tumor effects in the tumor microenvironment. So, here we have sort of a 3-legged approach. So, the vaccination approach against HPV really can generate a strong immune response initially, and that can be supported with the IL-12. And then you come in with anti-PD-L1 and to whatever extent the TGF data is relevant here. And so, you have this cocktail where you're generating tumor-specific responses with a vaccine, you're supporting them with IL-12, and then blocking PD-L1. And as we go back even a couple of abstracts we talked about, now we sort of have a cocktail right of approaches. And so, I think this is very exciting. It's unique in that, in these tumors, obviously, HPV is the driving force of cancer. So, developing a vaccine against that is fairly straightforward. But I really like this concept of bringing forward sort of a multi-dimensional immunotherapy approach. And we'll note they have previously presented data on this trial, I think last year at ASCO, actually. But what they see are pretty strong response rates, almost 30% range in PD-1 refractory tumors. Again, that's our area of really high unmet need. It's hard to read through how useful a PD-1 naive treated patient here, although the response rates were high. But to me, it's really those patients who had progressed on PD-1 where they're getting these responses that tells me that this really could be something that's useful and potentially could be expanded beyond just say head neck cancer to any HPV relevant malignancy. Dr. Diwakar Davar: Excellent! Now on to our last abstract. Abstract 2520, ‘Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].' The first author is Dr. Jacob Thomas. Jason, we've seen a lot of interesting intratumoral therapies. You and I have both done a lot of studies in looking at intratumoral agents from toll-like receptor agonists, TLR-9, TLR 7-8, and more recently, oncolytic viruses. So, contextualizing IT230-6 in the spectrum of intratumoral therapies, how do you feel about this drug, which is actually a very interesting novel drug. It's not just a TLR agonist, or for that matter, an OV, very interestingly, it's an intratumoral therapy that has actually got chemotherapy in it. So, how do you feel about this drug? How do you feel about the responses that we've seen? And particularly how do you feel about the setting in neoadjuvant breast cancer? Dr. Jason Luke: Yeah. I would pick up where you said that this drug INT230-6 is just a really interesting concoction. So, it's cisplatin mixed with vinblastine, in a specific amphiphilic molecule that allows it to diffuse in through the cancer. And so, if you had said that to me a few years ago, I would have looked at you and been like, ‘What are you talking about?' But I think the data that's been emerging for this is just really interesting because something about this chemotherapy cocktail actually drives immune responses. And really what the focus of this abstract is on is showing that you get an influx of CD foreign CDTa cells into the tumor microenvironment that's associated with a therapeutic benefit. I think that's just really, really interesting to think about. It sort of makes one wonder when we're doing these intratumoral injections, how much of it is just the injection, and how much of it is the therapeutic agent, but I think it's a really novel therapy, and one that appears to be very well tolerated as well. And that's also the exciting part. When you hear cisplatin and vinblastine, you think, ‘Oh, well, that's not going to work.' But apparently, it stays right in the tumor and generates these immune effects. I think it's very exciting. I think their approach here—going after what we usually call cold tumors, ones that don't respond to immunotherapy, you mentioned breast cancer—I think it's really interesting. I'm really looking forward to seeing the actual data from this abstract because, on first pass, it wouldn't have been what I thought about in terms of driving immune responses, but maybe it just goes to show that there's a lot more to understand there about immunogenic cell death and some of these other concepts that we bandy about. But I think this will be one of the most interesting abstracts actually to see the data for once it's available. Dr. Diwakar Davar: Great! Taking a slight pivot from that. You've been involved in the development of novel response endpoints. One of the issues that we have with intratumoral therapies is that you're measuring a lesion that you inject, so now you inject something and it gets a little bigger. Is it getting bigger because it's growing? Is it getting bigger because the drug is working? We don't know. We have now itRECIST, which you have been working on. What's very interesting is that whether you look at itRECIST, or RECIST, irRECIST, or imRECIST, when you have the monopoly of different response endpoints we have to deal with these days, these patients have monotherapy responses in non-injected tumors. How do you feel about that as a drug developer and somebody who's giving patients drugs like that? What is your impression of having shrinkage in the non-injected tumor? Dr. Jason Luke: I think it's really exciting about this concept of the abscopal effect that we've bandied about for years. Despite being an investigator in this space, I'm really excited to actually see the data and to understand what these out of field responses are. If it's really true that this is robust, I mean, it could potentially be like a game-changer kind of thing. But I'll reserve judgment until I see the actual scans of the tumors that actually shrank that weren't injected. Dr. Diwakar Davar: Fantastic insights, Jason. So, thank you for taking the time to join us on this podcast and to highlight these extraordinarily important advances in immunotherapy. Dr. Jason Luke: I appreciate the opportunity to participate today. Dr. Diwakar Davar: So, thank you, and thank you to our listeners for your time today, you will find the links to the abstracts that we discussed today in the transcript of the episode. Finally, if you're enjoying the content on the ASCO Daily News podcast, please take a moment to rate review and subscribe wherever you get your podcasts. So, thank you, Jason. And thank you to the team for putting this together. Disclosures: Dr. Diwakar Davar: Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Shionogi (Immediate Family Member), Vedanta Biosciences Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, Zucero Therapeutics (Inst), GSK, Merck, Arcus Biosciences Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231, and Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, Stipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences , Hotspot Therapeutics, SERVIER , STINGthera, Synthekine Research Funding (Inst): Merck, Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma, EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

covid-19 university health ai travel spring pittsburgh phase cd consulting stock results pfizer national institutes ils pivoting werewolf relation advances io american association mrna pd bayer immune pk abstract oncology hpv merck rna efficacy endeavor patents subsequent janssen novartis relativity posters royalties lag ov accommodations cancer care immunotherapy gsk asco genentech disclosures national cancer institute mrd phase ii abbvie bristol myers squibb stipe takeda regeneron gilead sciences adverse events medical oncology nektar onc texas md anderson cancer center tlr libretto prognostic cancer immunotherapy pd l1 eisai tgf asco annual meeting pyxis rubius servier ctla ctdna apcs incyte emd serono alnylam jacob thomas genmab moderna therapeutics clinical center cancer research aacr tesaro jason luke transcript dr recist arcus biosciences array biopharma cdta synlogic

Doctor Strange in the Multiverse of Madness with Jacob Thomas

Flyover Film Show

Play Episode Listen Later May 7, 2022 90:25

Doctor Strange 2 is Sam Raimi's first movie in nearly 10 years. Does it feel like a Raimi flick? Is it too gory or scary to take your kids? What about those cameos??Olivia and Isaac continue the conversation about their feelings surrounding the Marvel Cinematic Universe with guest Jacob Thomas of Three Dudes and a Movie Podcast. Are you ready for the madness?

movies hollywood film south madness strange midwest multiverse southwest marvel cinematic universe doctorstrange sam raimi strange in the multiverse movie podcast raimi three dudes jacob thomas

LowcoSports Lowdown

Play Episode Listen Later May 1, 2022

LowcoSports.com's Justin Jarrett and Wes Kerr keep you in the know with the latest sports news and analysis from the South Carolina Lowcountry in the LowcoSports Lowdown. This week's show includes golf news with Lowco golfers playing on the PGA and Korn Ferry tours this week, high school football recruiting news out of Bluffton, and a look at the spring sports playoffs, including an interview with Hilton Head High softball star and future Gamecock Reagan Marchant. THE LOWDOWN • Intro/check-in • Bryson Nimmer tied for 18-hole lead at Mexico Open with 7-under 64, Jonathan Griz competing at Korn Ferry Tour's Huntsville Championship • Jaylin Linder and Camauri Simmons earn offers from Presbyterian College • Who are some spring sports teams to keep an eye on in the playoffs? • Reagan Marchant interview • USCB softball battles Sun Conference tournament berth at home vs. Keiser, baseball notches huge series win at Ave Maria, Jacob Thomas finishes 2nd at TSC Golf Championship • Teams and Athletes of the Week Local sports content that is not sponsored is now available only to LowcoSports.com's Patreon supporters. Pledge your monthly support here for as little as $1 per month to ensure you have access to all of our grassroots LOCAL sports coverage!

BONUS EPISODE – Ep 4: Outtake

Three Dudes and a Movie

Play Episode Listen Later Apr 1, 2022 3:39

"Ryan, don't publish this ok." – Jacob Thomas, 2022*Ryan publishes outtakes episodeDid you guys know outtakes isn't spelled outakes? (TMYK)

outtake jacob thomas

Refine // Part 7: Pride - Humility // Jacob Thomas

Rolling Hills Community Church - Nolensville Campus

Play Episode Listen Later Mar 20, 2022 37:00

Pride is a sin that is often difficult to detect in our lives. Pride always keeps the focus on “self” and rejects our need for God. The closer we move towards intimacy with God the more we will understand what it means to “deny ourselves” and live in the fullness of the freedom we have in Christ. Through Christ, we understand what true humility is, and it is in that humility we become better leaders, family members, co-workers, and neighbors.

god jesus christ religion christianity pride tennessee humility refine through christ jeff simmons jacob thomas

Brit Clark of the Conrad Mansion Museum Alyssa Cordova of the Hockaday Museum of Art NW MT History Museum Jacob Thomas 3-14-2022

challenges mansion cordova history museum kalispell hockaday jacob thomas john hendricks robin mitchell

Play Episode Listen Later Mar 14, 2022 13:03

Brit Clark of the Conrad Mansion Museum, Alyssa Cordova of the Hockaday Museum of Art & NW MT History Museum Jacob Thomas joined the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Monday March 14, 2022 to talk about the Museum Directors Roundtable: Joys and Challenges of the Museum Profession in Kalispell on Sunday, 3/20 @ 2pm.

Ep 222: Is faith obsolete? | Jacob Thomas

Bigger questions

Play Episode Listen Later Feb 26, 2022 27:31

Does science render belief in God unnecessary?

god science obsolete jacob thomas

David Bowie

THE PITRE DISH

Play Episode Listen Later Feb 10, 2022 141:12

In this episode, Pitre & co-host Jacob Thomas, dissect & discuss the life & career of Rock & Roll Hall of Famer, David Bowie! --- Send in a voice message: https://anchor.fm/thepitredish/message

david bowie pitre jacob thomas rock roll hall of famer

NW MT History Museum Executive Director Jacob Thomas 2-1-2022

executive director executives history museum jacob thomas john hendricks robin mitchell

Play Episode Listen Later Feb 3, 2022 14:36

NW MT History Museum Executive Director Jacob Thomas joined the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Tuesday February 1, 2022 to talk about the first segment of 2022 John White Speaker Series featuring Flathead Lake Bio Station Tom Bansak as well as the additional speakers throughout the next few months.

NW MT History Museum Executive Director Jacob Thomas 1-4-2022

executive director executives history museum jacob thomas john hendricks robin mitchell

Play Episode Listen Later Jan 6, 2022 12:35

NW MT History Museum Executive Director Jacob Thomas joined the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Tuesday January 4, 2022 to talk about the 20th Annual John White Speaker Series that returns in a New-and-Improved Format!

Northwest Montana History Museum Executive Director Jacob Thomas 12-14-2021

executive director tales progress executives museum hardships chores glories history museum book signings northwest montana jacob thomas john hendricks robin mitchell

Play Episode Listen Later Dec 14, 2021 7:10

Northwest Montana History Museum Executive Director Jacob Thomas joined the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Tuesday December 14, 2021 to talk about Museum's Fourth Annual Holiday Open House and Book Signing with Local Author John Fraley and two newest exhibitions schedule to open; Tales of Ten Objects: Objects of Progress from the 1910s and Glories, Chores, and Hardships.

Executive Director NW MT History Museum Jacob Thomas, Conrad Manion Museum Director Brit Clark, Executive Director, Alyssa Cordova 9-15-2021

executive director executives cordova history museum museum director manion jacob thomas john hendricks robin mitchell

Play Episode Listen Later Sep 17, 2021 13:26

Executive Director NW MT History Museum Jacob Thomas, Conrad Manion Museum Director Brit Clark, Executive Director, Alyssa Cordova appeared on Glacier Bank Community Conversations on the KGEZ Good Morning Show with John Hendricks and Robin Mitchell on Wednesday September 15, 2021 to talk about the Locals Day this Saturday September 18.

Enjoy Trivia and more at NWMT History Museum

director history movies museum montana bar trivia membership visitors tours northwest guides residents venue history museum jacob thomas

Play Episode Listen Later Jun 24, 2021 3:00

In this episode of "What's Going On", Wendy Ostrom-Price talks with Jacob Thomas, Director of the Northwest Montana History Museum about trivia night, the movie club, and other fun events at the Museum for members and nonmembers alike!

Kalispell History on display at NWMT Museum

director history society museum montana visitors tours northwest display downtown railroads locals colorful guidebook kalispell jacob thomas

Play Episode Listen Later Jun 23, 2021 3:19

In this episode of "What's Going On", Wendy Ostrom-Price talks with Jacob Thomas, Director of the Northwest Montana History Museum about historical guides, tours and other big plans for the summer.

Highland Springs falls in state Class 5 football title game, 13-10

Monday Moms

Play Episode Listen Later May 2, 2021 6:45

You can’t win them all. That’s a reality that Stone Bridge High School head football coach Mickey Thompson knows all too well. Facing Highland Springs in the Class 5 State Championship for the fourth time in six years, Thompson and the Bulldogs were looking for their first win in those matchups. Thanks to an overtime touchdown pass from quarterback Billy Wiles to Jacob Thomas, they were able to accomplish that goal, defeating the Springers 13-10 on Saturday in the title game at Varina High School. “This was one of those games where it wasn’t good enough just to get here...Article LinkSupport the show (http://henricocitizen.com/contribute)

football class falls thompson bulldogs springs highland state championships title game springers jacob thomas mickey thompson

Binarybusters special: leadership in TGD communties

Out of the Pan

Play Episode Listen Later Mar 21, 2021

Kayleen White and Jacob Thomas talk leadership in TGD communities including self-care, boundaries, growth and humour

leadership tgd jacob thomas

Real Jesus Real Life // Ep 5: Real Men // Jacob Thomas

Thrive

Play Episode Listen Later Mar 16, 2021 28:09

jesus christ bible college real life young adults real men real jesus jacob thomas

John White Lecture Series Part II

director history state speaker series museum montana wilderness senators historians northwest lecture series john white fraley jacob thomas

Play Episode Listen Later Jan 5, 2021 3:23

In this episode of "What's Going On", Wendy Ostrom-Price talks to Jacob Thomas, Director of the Northwest Montana History Museum, about the 19th Annual John White Speaker Series.

John White Lecture Series Part I

director history speaker series museum montana bloom northwest lecture series john white fraley jacob thomas

Play Episode Listen Later Jan 4, 2021 3:20

In this episode of "What's Going On", Wendy Ostrom-Price talks to Jacob Thomas, Director of the Northwest Montana History Museum, about the 19th Annual John White Speaker Series.

SBG 56: Goldmember with Jacob Thomas

Lez Hang Out | A Lesbian Podcast

Play Episode Listen Later Dec 14, 2020 77:46

Leigh (@lshfoster) and Ellie (@elliebrigida) are joined by Jacob Thomas, LGBTQIA activist and best friends of the Duchess, to talk about why Austin Powers Goldmember Should've Been Gay. First of all, no straight man is that obsessed with other people's members and Goldmember literally turns them into gold to make them even more exciting! Frau is a lesbian icon, Number 2 and Basil would host the best and cleanest play parties and Austin is such a soft boy. Oh and how could we forget Foxxy Cleopatra/Beyonce giving us all of the gay feelings. Jacob had us in stitches and we know you will love them as much as we did! Use LEZDIVEIN for 25% off at diveindeck.com for your holiday stocking stuffers! Follow along on Twitter @lezhangoutpod and Facebook and Instagram (@lezhangoutpod). Support this show http://supporter.acast.com/lezhangoutpod. See acast.com/privacy for privacy and opt-out information.

lgbtqia duchess basil goldmember jacob thomas

94: Big 10 Decisive Decision / NFL & NCAAF Weekly Picks (Jacob T.)

nfl decision ohio state big ten decisive ncaaf weekly picks jacob thomas

Play Episode Listen Later Dec 11, 2020 54:20

We dive into the terrible decision of the Big 10 lowering its championship requirements for Ohio State. We are also joined by our close friend Jacob Thomas to break down and predict this weeks NFL & College Football Slate Follow us on any platform @BurgersBrats

94: Big 10 Decisive Decision / NFL & NCAAF Weekly Picks (Jacob T.)

nfl decision ohio state big ten decisive ncaaf weekly picks jacob thomas

Play Episode Listen Later Dec 11, 2020 54:20

Independent MP Ali Cupper; Activist and Performer Jacob Thomas on Mental Health

interview mental health independent midnight activist sovereignty lifeline performer mildura kulin nation 3cr qlife fiona patten jacob thomas reason party

Play Episode Listen Later Dec 11, 2020

Interviews with Ali Cupper and Jacob Thomas. Independent MP Ali Cupper discusses her Mildura electorate, social justice issues, including conversion practices, and her new coalition with Fiona Patten's Reason Party. Performer, activist and advocate Jacob Thomas discusses their mental health awareness journey. QLife 1800 184 527, 3 pm to Midnight every day. Rainbow Door (Victoria), 10 am to 6 pm every day, phone 1800 729 367, sms 0480 017 246 or email support@rainbowdoor.org.au Lifeline 13 11 14. 3CR broadcasts from the stolen lands of the Kulin Nation. Sovereignty was never ceded.

FNL Globe Awards 2020 INTERVIEW series – Jacob Thomas

Friday Night Live with David and Sue

Play Episode Listen Later Dec 6, 2020 5:45

David and Sue interview a number of people connected with the GLOBE COMMUNITY AWARDS 2020 prior to the awards ceremony on 04 December 2020. First cab off the rank –... LEARN MORE The post FNL Globe Awards 2020 INTERVIEW series – Jacob Thomas appeared first on David and Sue.

interview awards globe jacob thomas

013: United States of Idiot

Same Brand of Idiot

Play Episode Listen Later Nov 5, 2020 67:50

Where is it illegal to fall asleep in a cheese factory? Which president hates broccoli? Sam and Lisa are joined by a close friend this week to answer these important questions. Featuring the host of Out in the Woods Podcast, Jacob Thomas. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

united states idiots woods podcast jacob thomas

53. Job hunting and career progression for the trans, gender diverse, and nonbinary professionals - With Jacob Thomas.

The Job Hunting Podcast

Play Episode Listen Later Oct 26, 2020 56:10

I invited Jacob Thomas to be a guest on the podcast so that they could help me unpack some of the many questions I have about how employers, recruiters, and coaches can better support trans, gender diverse, and nonbinary professionals. And Jacob did not disappoint. This is a much-needed discussion that I hope all my listeners will be interested in for their personal and professional development. Some of the topics of our conversation include: choosing pronouns, employers and organizations looking for quick wins with what Jacob explains is “pink” dollar the recruitment of queers employees to reach diversity markers issues with dress codes conscious and unconscious bias Jacob's experience in changing their gender marker with their employer and much more. Jacob and I are friends, so the first 12 minutes is a bit of banter, where at least twice, I cried with laughter. If you want to check out the video interview, please go to my YouTube channel, where many of the podcasts are also available in video format. About our guest, Jacob Thomas: Jacob Thomas is one of Australia's most prominent leaders in sexual orientation and gender identity. A nonbinary person living in Melbourne, Jacob uses the pronouns they/them and works at the Monash Warwick Alliance as their Education Project Coordinator, where they also guest lecture in Global Studies. In 2016 Jacob received the Queen's Young Leader Award, recognizing Jacob's work on suicide prevention for Australia's LGBTIQ community. Jacob previously sat as the Coordinator of the Commonwealth Youth Gender and Equality Network (CYGEN) and represented the network at international levels such as the 61st session of UN Women's Commission on the Status of Women (CSW) and the ECOSOC Youth Forum in New York, the Duke and Duchess of Sussex, the 11th Commonwealth Youth Forum in London, and at AIDS2018 in Amsterdam. Jacob advises public, private, and non-profit organizations on issues related to the LGBTIQ community, diversity and inclusion policies, and queer-friendly work environments. They are a mentor to many queer, allies, and senior leaders in Melbourne and internationally. A greater speaker and facilitator, Jacob, has presented a TEDx Talk at QUT on the ideas around gender identity, is a contributor to Archer Magazine and Star Observer, and has written a personal essay for BuzzFeed about their experience coming out as nonbinary. Jacob is interested in queer perspectives in intercultural learning, feminist methodologies, and youth leadership. They are currently undertaking their Masters in International Development at RMIT. In their spare time, Jacob is a performer, designer, and sometimes drag artist. About your host: Hello, and welcome! I'm Renata Bernarde, the Host of The Job Hunting Podcast. I'm also a virtual career coach, job hunting expert, and career strategist. I teach professionals in the corporate, non-profit, and public sectors the steps and frameworks to help them find great jobs, change, and advance their careers with confidence and less stress. If you are 1) an ambitious professional who is keen to develop a robust career plan, 2) looking to find your next job or promotion, or 3) you want to keep a finger on the pulse of the job market so that when you ready and an opportunity arises, you can hit the ground running – then this podcast is for you. In addition to The Job Hunting Podcast, I've created a series of free tools and resources. I developed a range of services for professionals in career or job transition. And of course, I also coach private clients. So there is really no excuse – I'm determined to help you! I want you to feel empowered, nail your next job, and have the career you want. Free tools & where to listen to The Job Hunting Podcast: My website Subscribe to the newsletter and access free tools to help you advance in your career Where to listen/subscribe/follow to The Job Hunting Podcast. Links mentioned in this episode: This Podcast in a video on YouTube. Jacob's chapter in the 'Encyclopaedia for the UN Sustainable Development Goals, published by Springer: Youth and Their Role in Attaining SDG5' Jacob's LinkedIn The Job Hunting Podcast Episode 45. The future of offices and teamwork - with workplace strategist Su Lim French Movie Amelie French series Dix Pur Cent (Call My Agent) What you get when you google Jacob Thomas and Prince Harry ACON Transgender Victoria Download a transcript of this episode Please support this podcast: Follow, subscribe, rate, and review us (iTunes only). Please consider rating and reviewing my show. This helps me reach more people like you who want guidance and support in job hunting and career advancement! Click here, scroll all the way to the bottom, tap to rate with 5 stars, and select "Write a review." Then let me know in a few words what you think about the show and how it has helped you. And you haven't already, don't forget to subscribe! Enjoy the episode and Ciao for now RB Renata Bernarde | Virtual Coach | Career Management Strategist | Job Hunting Expert Host, The Job Hunting Podcast Founder & Chief Coach, Pantala Academy Managing Director, Pantala Pty Ltd Level 14, 333 Collins Street, Melbourne Victoria 3000 Australia Book a time to discuss 1-1 coaching and achieve your goals faster rb@renatabernarde.com https://www.renatabernarde.com

new york australia masters write melbourne amsterdam status commission transgender coordinators buzzfeed professionals tedx talks sussex ciao duchess nonbinary sustainable development goals international development lgbtiq job hunting un women rmit global studies career progression qut gender diverse melbourne victoria jacob thomas collins street women csw young leader award archer magazine star observer

TRAILBLAZER: How to start a global impact driven career? W/Jacob Thomas

Global Questions

Play Episode Listen Later Oct 19, 2020 36:01

Gen (She/Her) talks with Jacob Thomas (They/Them) about how they started their career path and how it led them into advocacy, equality projects and public speaking. Jacob Thomas is an expert in Mental Health, Human Rights and LGBTIQI+ equality. They have written a chapter on the Sustainable Development Goal 5 (SDG5): Gender Equality and Women's Empowerment, focusing on Youth and their role in attaining SDG5. They currently work as the Alliance Education Project Coordinator at Monash Warwick Alliance, and previously have worked as the Coordinator at the Commonwealth Youth and Gender Equality Network. They have met the Queen, been ban from certain countries and have worked on many grass-root equality projects. In this episode, Gen and Jacob discuss: - What it means to be an advocate and work in human rights - How to be the best ally and check your privilege - How you can make a difference in some difficult spaces of inequality Follow Jacob Thomas on Instagram or LinkedIn. Youth and Their Role in Attaining SDG5 by Jacob Thomas Reform 53, a project Jacob mentioned by the Commonwealth Youth and Gender Equality Network. FOLLOW US: Follow Global Questions on Instagram, Facebook and Twitter for more content! Find more about Young Diplomats Society on our website. CREDITS: This episode is produced by Young Diplomats Society on the lands of the Wurundjeri/Gadigal people. We pay our respects to the traditional custodians of the lands upon which we operate and live.

women mental health career youth empowerment driven human rights coordinators trailblazer sustainable development goals global impact jacob thomas

Missionary Preparation and being on the Lord's Errand with Elder Jacob Thomas

Church of Jesus Christ Alliance Texas Stake Podcast

Play Episode Listen Later Oct 2, 2020 24:36

lord preparation elder missionary errand jacob thomas

Kitty Chrystal, queer duo Nite Fruit; non-binary activists Jacob Thomas and Joel Murray

interview fruit mine queer sovereignty activists nonbinary nite kulin nation 3cr joel murray jacob thomas

Play Episode Listen Later Aug 21, 2020

Interviews with three non-binary guests: Kitty Chrystal from queer music duo Nite Fruit and activists Jacob Thomas and Joel Murray. Nite Fruit are Kitty Chrystal (pic left) and Prani Harrison. We open the show with their new single Mine, from their newly released EP Disintegrate and chat with Kitty about their music. https://www.facebook.com/nitefruitband Jacob Thomas talks about their activism, artistery and teaching during lockdown. https://www.facebook.com/jacob.thomas.7737 Joel Murray shares their experiences after recently coming out as non-binary. https://twitter.com/joelamurray 3CR broadcasts from the stolen lands of the Kulin Nation. Sovereignty was never ceded. https://www.qlife.org.au/

New York City Draft Riots of 1863

The History Book

Play Episode Listen Later Jul 14, 2020 31:15

Join in and listen as host Jacob Thomas details the events leading up to and surrounding the July 1863 Draft Riots in New York during the American Civil War. This episode also dives into the aftermath and effects of the riots on the city as well! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

new york new york city american civil war jacob thomas draft riots

New York City Draft Riots of 1863

The History Book

Play Episode Listen Later Jul 14, 2020 31:15

new york new york city american civil war jacob thomas draft riots

Jacob Thomas Jr

DittyTV's Insights | Artist Interviews

Play Episode Listen Later May 29, 2020 18:10

Born and raised in Southern Louisana, one listen and Jacob Thomas Jr. would have you figuring he spent his youth performing in cowboy bars and trucker dives. You'd only be half right. While Saturday nights were spent cavorting with sinners, Sunday mornings would find him, albeit hungover at times, entertaining saints. Recorded Dec. 2018 See omnystudio.com/listener for privacy information.

jacob thomas

Research - Dale & Thomas Interview

AAOMPT Podcast

Play Episode Listen Later Apr 30, 2020 39:36

Drs. Philip Dale and Jacob Thomas of KORT (Kentucky Orthopedic Rehab Team) and Orthopaedics Plus Physical Therapy, respectively, are interviewed by Stephen M. Shaffer regarding a publication titled, “Physical therapist clinical reasoning and classification inconsistencies in headache disorders: a United States survey.”

united states research drs jacob thomas

Ep. 40 Dale & Thomas Interview

AAOMPT Podcast

Play Episode Listen Later Apr 30, 2020 39:36

Drs. Philip Dale (e-mail, Twitter, LinkedIn) and Jacob Thomas (e-mail, Twitter, LinkedIn) of KORT (Kentucky Orthopedic Rehab Team) and Orthopaedics Plus Physical Therapy, respectively, are interviewed by Stephen M. Shaffer regarding a publication from the Journal of Manual and Manipulative Therapy titled, “Physical therapist clinical reasoning and classification inconsistencies in headache disorders: a United States survey.” This episode contains information that will be interesting for practitioners who want to know more about how well physical therapists perform when attempting to identify headache patterns. Additionally, for anyone interested in the ICHD criteria mentioned during this interview, they can be found at this link.Find out more about the American Academy of Orthopaedic Manual Physical Therapists at the following links:Academy website: www.aaompt.orgTwitter: @AAOMPTFacebook: https://www.facebook.com/aaompt/Instagram: https://www.instagram.com/officialaaompt/?hl=enPodcast e-mail: aaomptpodcast@gmail.comPodcast website: https://aaomptpodcast.simplecast.fm

united states healthcare academy journal medical manual american academy drs physical therapy headaches orthopedics shaffer manual therapy jacob thomas manipulative therapy aaompt

EP 009 - Interview with Dan Guerin, Jacob Thomas, & Dustin Seyersdahl

Sharper Podcast

Play Episode Listen Later Apr 9, 2020 31:53

Gary sits down with the guys from Cincinnati to talk about their story and where they see themselves headed in the future.

cincinnati guerin jacob thomas

Offies 2020 -Audio

That Stagey Blog

Play Episode Listen Later Mar 10, 2020 70:31

Offies 2020. Battersea Arts Centre Performances from: Arts Ed* Bac Beatbox Academy Interviews with Oti Mabuse Joanne Clifton Jack Reitman Cary Crankson Geoffrey Brown Ft. Winning speeches from Park Theatre Arcola Theatre Above The Stag Chickenshed Theatre Bunker Theatre Jack Studio Theatre All the Little Lights Napoli 44 Unicorn Theatre Half Moon Theatre Oti Mabuse Southwark Playhouse Jordan Li-Smith Queen of the Mist Jack Studio Theatre Charing Cross Theatre Amour Charing Cross Theatre ‪Danielle Tarento ‬ Jerome Pradon Aspects of Love Ashlee Young The Union Theatre Bart Lambert The Hope Theatre Jeannette Bayardelle The Vaults Bill Buckhurst Boulevard Theatre Greenwich Theatre HMS Pinafore Charles Court Opera King’s Head Theatre Tobi Kyeremateng Adrian Gee Diego Pitarch The Pleasance Jessica Hung Han Yun English Touring Theatre Theatre Royal Stratford East Ben Bull ‪Baby Reindeer Bush Theatre Matt Eaton Guildford Shakespeare Company Jermyn Street Theatre Sex Sex Men Men Pecs Drag Kings Yard Theatre Operation Mincemeat New Diorama The Curious Case of Benjamin Button Queens of Sheba Chris Sonnex ‬ Dylan Coburn Gray CitySong Soho Theatre Ross Willis Wolfie Theatre503 John Sackville Finborough Theatre Marina Bye Coronet Theatre Country Music Omnibus Theatre Gemma Barnett A Hundred Words for Snow Trafalgar Studios Ned Bennett Equus Mehmet Ergen Leyla Nazli Closing words from: Winsome Pinnock * Cast Nic Myers. Kingsley Morton. Tanisha-Mae Brown. Jacob Thomas. Beth Dare. Jay Albray. Henry Shine. Elliott Swan. Harry Lambert.

winning jacob thomas offies

Fringe with Jacob and Selina

Out of the Pan

Play Episode Listen Later Sep 14, 2019

A chat with two artistes beind two of many fab Fringe shows: Transgression with Jacob Thomas (they/them) and Boobs with Selina Jenkins (she/her)

boobs fringe transgression jacob thomas

Creatrix Tiara, Sister Spit; Jacob Thomas, Stop Deportations To Danger; Kate Foord and Katie Cullen, Renegade Pub Footy and Inclusion

manchester united one step old trafford video assistant referee var jacob thomas

Play Episode Listen Later Aug 23, 2019

Creatrix Tiara talks about touring with Sister Spit in the United States in 2020 and Mama Alto's surprise birthday party at Hares and Hyenas.Jacob Thomas discusses Stop Deportations To Danger, a campaign to stop QANTAS being a carrier for the deportation of refugees and asylum seekers.Katie Cullen and Kate Foord from Queerspace at Drummond Street Services talk about Renegade Pub Footy and inclusion in sport and its impacts on mental health.3CR broadcasts from the stolen lands of the Kulin Nation. Sovreignty was never ceded in this country.Language warning: this episode includes music by Sonic Youth with coarse lyrics.

united states language danger inclusion renegade deportation footy qantas sonic youth hyenas hares kulin nation 3cr jacob thomas katie cullen sister spit queerspace mama alto sovreignty drummond street services creatrix tiara

One Step too 'VAR'? (feat. Jacob Thomas)

For Football's Sake

Play Episode Listen Later Aug 18, 2019 13:26

Episode #2: One Step too 'VAR'? This is the FFS Podcast. Welcome to Episode #2. Joining me in today's episode is Jacob Thomas - a lifelong Manchester United fan who, recently, had the opportunity to watch the club's opening game at Old Trafford. Together we dissect the criticisms levelled up on one of the most controversial elements introduced into the footballing world - Video Assistant Referee (VAR). From delays in decision making to transparency amongst those at the stadium and us sitting at home, was it worth the wait? Click on the link below to subscribe to our Instagram account and keep up to date with our podcast! https://www.instagram.com/ffspodcast

Along came Poly

Sex and The Music City

Play Episode Listen Later May 17, 2019 61:18

Talk about having your cake and eating it too! The girls talk to Nashville touring musician Jacob Thomas about his unconventional love life. They discuss the lifestyle around non monogamy, polyamory, and how it’s possible to be in love with more than one person at the same time without hurting anyone.

talk nashville poly along came jacob thomas

Episode 11; Super Bowl Recap (Jacob C. & Jacob T.)

super bowl nba all star super bowl recap jacob thomas

Play Episode Listen Later Feb 7, 2019 40:41

We talk Super Bowl recap, NBA deadline who who we would draft for the All-Star game! Jacob Clements & Jacob Thomas join the show!

Episode 11; Super Bowl Recap (Jacob C. & Jacob T.)